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Nigeria has a high burden of tuberculosis but the drug resistant situation was previously unknown.
This report evaluates the firstline drug resistance and associated factors among chronic tuberculosis cases from
the tuberculosis control programme in South south and South east zones of Nigeria.
Descriptive study of chronic tuberculosis patients consecutively referred from March 2003 to
December 2005. Information collected by indepth interview of patients and tuberculosis microscopy, culture
and sensitivity of patients sputum.
Of 82 patients infected with M. tuberculosis strains, 57(64.0%) were males while their mean age was
38.0 13.2 years. Fifty nine (72.0%) patients had multidrug-resistance tuberculosis with 35(42.7%) resistant to
rifampicin, isoniazid, ethambutol, streptomycin while 14(17.1%) had poly-drug resistance and one patient had
monoresistance to isoniazid. Within and outside the national control programme, drug therapy was
inappropriate (69.5-81.7%) and treatment poorly supervised (26.8-39.0%). Factors associated with multidrug
resistance were a male age less than 45years and Category 1 treatment in a private health facility.
The multidrug resistance burden in chronic tuberculosis cases is very high in southern Nigeria
and should be urgently and adequately controlled in the interest of public health.
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INTRODUCTION
Multi-drug resistant tuberculosis is an emerging
global problem which is threatening control
programmes in many settings. The treatment of
multi-drug resistant tuberculosis involves the use of
second line drugs which are usually very expensive,
highly toxic, of lower efficacy and requires costly
laboratory support. The most cost effective strategy
for control of multi-drug resistant tuberculosis is the
early identification and control of the factors that led
to its emergence accompanied by treatment of those
already infected.
Nigeria presently ranks fourth among the 22 high-
burden tuberculosis countries world-wide while
being the country with the greatest number of
estimated tuberculosis cases in Africa. However, in
TB control efforts, the country recorded a DOTs'
coverage of 65%, a smear positive case detection rate
of 22% and a treatment success rate of 73% in the
year 2005. Coordinated tuberculosis control started
in the country in 1988 with the establishment of the
tuberculosis control programme as a separate unit
under the Department of Disease Control and
Primary Health Care of the Federal Ministry of
Health. At programme inception in 1994, the drug
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Regimens in use for adults were 2SRHZ/6TH or
2STH/10TH for Category I treatment and
2SRHZE/1RHZE/5TH or /5R3H3E3 for Category II
treatment. These were later changed in 2000 to the
regimens; 2RHZE/6HE or /6TH for Category I
treatment while 2SRHEZ/1RHEZ /5R3H3E3 was
retained for Category II treatment. DOTS strategy is
the adopted practice forTB control in the country. The
epidemiology of tuberculosis in Nigeria is the same as
for the rest of Africa, with tuberculosis notification in
males higher than for the females and the age specific
rates highest for the 24-34 years age group.
The South-south and South-east zones of Nigeria are
made up of 11 of the 36 states of the country with an
estimated population of 36,340,241 in the year 2005 .
Both zones have had tuberculosis support in the form
of provision of training, mobility, drugs, laboratory
equipment, and supplies from the German Leprosy
Relief Association since 1994 . A few years into the
implementation of the TB control programme, health
workers in both zones started encountering “suspect”
MDRTB cases but drug resistance surveillance data
was unavailable. Factors implicated in the
propagation of MDR-TB in other nations exist in the
country, namely; a high default rate of TB cases on
treatment, an increased burden of HIV /AIDS, the
availability of TB drugs over the counter, and







unsupported health providers in both government
and private health facilities.
The objective of this study was to describe the 1st
line TB drugs resistance pattern in the chronic TB
cases arising from the control programme in the
South-south and South-east zones of Nigeria. The
possible factors associated with the emergence of
multi-drug resistance tuberculosis were also
determined.
We conducted a descriptive review of all chronic TB
cases referred for further evaluation by the National
Tuberculosis and Leprosy Control Programme
(NTP) to the Tuberculosis Unit of the University of
Nigeria Teaching Hospital , Enugu from March 2003
to December 2005. The chronic TB cases were
composed of the failures, relapses, and smear
positive returning defaulters of the NTP retreatment
regimen who were referred with their past medical
records and additionally gave a written consent to be
studied. Cases were excluded if the sputum culture
could not be done or was negative or contaminated
and a replacement could not be obtained. On referral,
each patient was interviewed by a medical doctor and
the following information was obtained using a
study proforma; patient's place of residence and
origin, age, sex, marital status, occupation,
household size, history of previous TB treatment,
diagnostic smear reports, drug regimens and
dosages, mode of supervision of treatment, treatment
outcome, HIV status and contact details. Patients
also submitted two sputum samples for TB
microscopy, culture and drug susceptibility test
(DST). Information obtained by interview was
crosschecked with those from patient's past medical
records. NTP personnel were also interviewed for
clarification and explanations of some treatment
delivery processes.
The two sputum samples from each patient were
decontaminated using the Petroff method and
smeared by Ziehl Neelson method for microscopy.
One plain and one pyruvate enriched Lowenstein-
Jensen slopes were then inoculated from each
sample and incubated at 37 C. Species identification
was done on one isolate per patient to differentiate
species of Mycobacterium tuberculosis complex
from those of atypical mycobacteria, using the
following biochemical properties; growth rate,
colonial morphology, nitrate reduction, catalase
reaction, growth in the presence of p-nitrobenzoic
acid and thiophen-2-carboxylic acid hydrazide,
pigment production in the light and dark.






Procedure for culture and species identification
Procedure for drug susceptibility test
Loewenstein Jensen medium using the economic
variant of the proportion method on the two isolates
from each patient. Procedure for the preparation of
media, stock solutions, bacterial suspensions and
dilutions, inoculation of media, incubation, reading
and reporting of the DST were according to the
format suggested by H.Rieder et al. Resistance was
taken as the percentage of colonies on the drug
containing media in comparison to the growth on the
drug free media. The criterion for resistance was 1%
growth for the following drugs at these
concentrations (ug/ml); rifampicin (40.0), isoniazid
(0.2), streptomycin (8.0) and ethambutol (2.0).
Where there were 5 or fewer colonies on the primary
culture or if a clear interpretation of results could not
be made, DST was assumed to be unreliable and was
repeated.
Internal quality control of laboratory procedures
included monitoring of the culture contamination
rate, temperature of the incubator, rate of negative
culture results in smear positive specimens and
purchase of drug powder for sensitivity tests from
reputable firms. Also, susceptibility test was done on
the standard H37RV strain for each new batch of
medium and for each drug following standard
procedures.Astandard operating procedure was used
for all laboratory activities. Instructions and scales of
measurement were incorporated into all the forms
used for data collection. All the survey procedures
and instruments were pilot-tested during the
preparatory phase. International quality control of
laboratory procedures involved a proficiency testing
scheme organized for the project laboratory by a
Supranational Reference Laboratory (Medical
Research Council, Pretoria, South Africa). At the
beginning of patient recruitment, proficiency test
showed a laboratory efficiency of 80% for
Ethambutol, 85% for Streptomycin, 90% each for
Isoniazid and Rifampicin; and a specificity of 84.6%
for ethambutol, 100% each for streptomycin,
rifampicin and isoniazid while the sensitivity was
71.4% 77.8% for all drugs. One of the strengths of
the study design is the representativeness of the study
population. Transportation reimbursement was done
for study respondents to encourage participation.
There may be a limitation of the accuracy of patients'
recall of prior TB treatment.
Standard case definitions for all variables were used.
Adequacy of drug regimen means its appropriateness
in terms of drug composition or dose for the category
ofTB being treated.
Ethical clearance for this study was obtained from the
University of Nigeria Teaching Hospital Ethics
Committee.
Epi-Info 2002 software was used for data analysis,
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facilities - 9(50%) cases and NTP - 5(14.3%) cases.
(X2=16.4, DF=2, p=0.0003). DOT practice during
the intensive phase of this treatment course was not
associated with greater MDRTB prevalence. At the
stage of WHO category 11 disease, majority of cases
64(78.0%) were treated by NTP but drug therapy was
inappropriate for most patients 67(81.7%).
Inappropriate therapy was administered on
49(76.6%) cases treated by NTP and on all 18
(100.0%) patients managed outside NTP (Fisher
exact p-value = 0.033). The forms of inappropriate
therapy reported were administration of inadequate
regimens {27(55.1%) cases by NTP and 16(88.9%)
cases outside NTP} and suboptimal dosing of 24
patients {22 (44.9%) cases within NTP and 2 (11.1%)
cases outside NTP}. DOT was not practiced mostly
by non-NTP facilities 12(66.7%) of 18 cases unlike
within NTP 10(15.6%) of 64 cases. (Fisher exact p-
value = 0.00006). DOT practice was a predictor of
MDRTB rather than the type of health facility and
appropriateness of drug regimens in this second
treatment course. An average of 3.2 ±1.2 courses of
treatment was received by the patients and the
number of TB treatment courses received was not
asociated with MDRTB (p-value: 0.496).
On investigating the number of patients that have had
contact with second line drugs, three patients had
ciprofloxacin added to a failed retreatment regimen
while one patient had both ciprofloxacin and
kanamycin added to a second retreatment regimen.
The last patient was later referred to South Africa on
request.
Table 1:
*INH, isoniazid; RIF, rifampicin; EMB, ethambutol;
SM, streptomycin. # Unlike other rows, cells in this
row are not mutually exclusive.
First-Line Drug Resistant Pattern in
Chronic Tuberculosis Cases in South Nigeria,
2003-2005 (N = 82).
Chi square test, Student T test, Fisher exact 2-tailed
test and Odds ratio at 95% Confidence Limits were
used to verify the significance of findings.
A total of 126 patients were referred within the study
period. Forty two patients were excluded from
analysis for the following reasons; 37 patients had
incomplete culture or DST results or past medical
records or lack evidence of Category 11 TB
treatment while 7 patients were infected with
atypical mycobacteria. The findings on 82 cases
whose isolates belonged to species of
Mycobacterium tuberculosis complex and who had
complete culture/DST results/ records of past TB
treatment are presented.
They were 51(62.2%) males and 31(37.8%) females.
Their age range was 15-80years while their mean age
was 35.6 11.5 yrs. Of these 82 patients, 59(72.0%)
had multidrug resistant TB with 35 (42.7%) cases
resistant to all the four drugs tested. Resistance to
three drugs, namely streptomycin and ethambutol
with either rifampicin or isoniazid resistance was
seen in 14(17.1%) cases. Monoresistance was
observed in 1(1.2%) patient while another patient
1(1.2%) had isolate sensitive to all drugs. The overall
resistance to streptomycin was 75(91.5%), isoniazid
76(92.7%), rifampicin 64(78.1%) and ethambutol
50(61.0%). See Table 1 for the details.
Males who were less than 45years were more likely
to have MDRTB than others. Of 61 (74.4%) patients
whose HIV status were known, only 6(9.8%) cases
were HIV positive. All the 6 (100.0%) HIV infected
patients had MDRTB as opposed to 72.8% of the
non-HIV infected cases but this difference was not
significant (95% CI: 0.0-2.6). See Table 2.
At the stage of WHO category 1 disease, 35(42.7%)
cases were treated by NTP, 22(26.8%) by private for
profit facilities, 18(22.0%) by government hospitals
and 7(8.5%) by drug stores. Both univariate analysis
and logistic regression identified category 1 disease
treatment by private for profit (PP) facilities as a
predictor of MDRTB. Drug therapy was
inappropriate for most patients 57 (69.5%) but it
was not a predictor of MDRTB. However, therapy
was significantly inadequate for all 29 (100%)
patients treated by PPfacilities / drug stores followed
by 15(83.3%) of 18 cases treated by unsupported
Government facilities and in 13(37.1%) of 35 cases
treated by NTP. (X2=31.7, DF=2, P-value =
0.0000001). The forms of inadequate therapy
observed were administration of unapproved
regimens (5.7% cases by NTP and 93.6% cases
outside NTP) and under dosing of patients on correct
regimens (all 11 cases within NTP). DOT was not
practised mostly in PP units / drug stores -18(62.1%)
cases followed by unsupported Government
RESULTS
Pattern No. (%) Resistant 95% CI
Fully sensitive 1 (1.2) 0.0-6.6
Monoresistance (total) 1 (1.2) 0.0-6.6
INH 1 (1.2) 0.0-6.6
Polyresistance (total) 21 (25.6) 16.6-36.4
INH + SM 7 (8.5) 3.5-16.8
INH + SM + EMB 9 (11.0) 5.1-19.8
RIF + SM + EMB 5(6.1) 2.0-13.7
Multidrug resistance (total) 59 (72.0) 60.9-81.3
INH + RIF 4 (4.9) 1.3-12.0
INH + RIF + EMB 1 (1.2) 0.0-6.6
INH + RIF + SM 19 (23.2) 14.6-33.8
INH + RIF + EMB + SM 35 (42.7) 31.8-54.1






The study identified a pool of highly infectious
patients with drug resistant tuberculosis 98% of
which required second line TB drugs that are
presently not provided by NTP. Their MDRTB
prevalence of 70% is unprecedented and is only
comparable to what was found in previously treated
patients in Colombia and Lithuania of the former
Soviet Union . To further worsen the drug resistant
situation in Nigeria, fluoroquinolones can be bought
without prescription in the open drug market and
from this report; some physicians are adding them to
a failing retreatment regimen. It is yet to be
investigated whether the patient who had
ciprofloxacin and kanamycin added to a failed repeat
retreatment regimen and was later referred to South
Africa for second line treatment was harboring the
XDR strain. Who knows the number and nationality
of people infected during that 6 hours international
flight! The patients with the fully sensitive and mono
resistant strains suggest new exogenous re-infection
which has been incriminated as a cause of recurrent
TB. However, molecular epidemiological studies
are needed to determine the transmission pattern in
the study area.
The sex and age distribution of these chronic TB
cases are similar to what has been observed among
both new and previously treated cases in Nigeria and
other settings. From the study, a male age less
than 45 years was associated with greater MDRTB
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males in connection with occupation may be the
reason for their increased MDRTB rate. In contrast to
past findings, HIV co-infection was not a predictor of
MDRTB. However, there were two main limitations
in this prediction; firstly only two-thirds of cases
were screened for HIVinfection and secondly a high
early mortality of co-infected cases in the study
environment is expected due to the absence of both
ART and second line drugs.
This report shows gross mismanagement of these
patients within and outside NTP and points towards a
health sector induced multi-drug resistance problem
in the study area. The first facility chosen for TB
management appears to be very pivotal to the overall
subsequent treatment outcome and private sector TB
management was associated with greater MDRTB
prevalence. Reports from the present and past studies
show that, tuberculosis treatment in the private
sector entailed prescription of untested and
unapproved drug regimens whose procurement from
a poorly regulated drug market is at the discretion of
the patient. In most instances, the ingestion of these
drugs is not directly observed. Private sector formal
involvement with TB control has been very minimal
in Nigeria though they are important health care
providers for the general populace. And like in other
countries, the high price of their non-involvement is
the emergence of drug resistant tuberculosis due to
the synergic interaction of inadequate drug regimens,
poor quality drugs and poor treatment supervision.






Table 2: Characteristics and Past Treatment Practices by MDR Status for Chronic Tuberculosis Cases in
Southern Nigeria, 2003-2005.
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Features Total No. (%) MDR Multivariate Logistic Regression
(95% CI) (95% CI)
Male age (years):
< 45 39 32 (82.1) (1.3-33.1)
= 45 12 5 (41.7)
Female Age (years):
< 45 25 17 (68.1) (0.008-4.9)
= 45 6 5 (83.3)
1st Therapy:
Right 25 17 (68.0) (0.2-2.4) (0.2-3.4)
Wrong 57 42 (73.7)
1st DOT:
Yes 50 38 (76.0) (0.5-4.9) (0.9-10.2)
No 32 21 (65.6)
2nd Facility:
NTP 64 44 (68.8) (0.07-1.8) (0.8-27.8)
Private unit 11 10(90.9) (0.5-203.6)
Govt facility 4 2(50.0) (0.03-5.5)
Drug store 3 3(100.0) (undefined)
2nd Therapy:
Right 15 11 (73.3) (0.2-5.2) (0.1-3.6)
Wrong 67 48 (71.6)
2nd DOT:
Yes 60 46 (76.7) (0.6-7.2) (1.0-17.9)
No 22 13 (59.1)
during category II treament can be interpreted as an
aftermath of regular and prolonged inappropriate
therapy in patients with some form of drug
resistance.
Treatment by NTP was not a risk factor for MDR-TB
but three main problems were identified with their
service delivery. Firstly is the problem of poor
history taking which led to patients with WHO
category 11 disease being misclassified as new cases
and their subsequent treatment as such. Secondly is
the problem of suboptimal drug dosage which arose
indirectly from drug packaging. For the intensive
phase of both category I and II treatment, the NTP
procures blister pack containing ethambutol,
pyrazinamide and rifampcin-isoniazid tablets
appropriate for patients weighing 40-55kg while
loose drugs are added to this blister pack for patients
weighing more than 55kg but this was not done for
some patients. Furthermore, isoniazid and
ethambutol were in some cases not increased for
intermittent administration during the continuation
p h a s e o f c a t e g o r y I I t r e a t m e n t w i t h
2SRHEZ/1RHEZ/5R3H3E3. However, ignorance of
correct drug dosages and reasons for the dosages
among NTPpersonnel and health workers may be the
problem though the programme manual is in order.
Thirdly is the problem of non-practice of DOT
during category 1 and II treatments. Similar
deficiencies in the prescription and dosages of
antituberculosis drugs have been reported in Malawi,
Nepal, Kenya and Senegal. The consequences of
such deficiencies are very costly and should not be
tolerated by the control programme. Standard
primary and acquired drug resistance survey is
needed in this setting to determine the adequacy of
the NTPreccomended regimens.
These research findings made tremendous impact on
TB control activities in the country. Firstly,
awareness of the mechanism of TB drug resistance
has been created among NTP personnel and ways of
minimizing its emergence partly addressed.
Secondly, the TB drug blister pack implicated as
contributing to the emergence of MDR-TB has been
changed and a new dosage-friendly 4-FDC pack is
already in use. Also, NTP added the regimens
2RHEZ/4RH for category I treatment to and
2SRHEZ/6RHEZ for category II treatment. The
study also lends support to the new global strategy of
making DOTS-plus widely available for TB control
especially in Nigeria for the identified pool of
chronic tuberculosis cases considering the size of the
population at risk.
This investigation received financial support from
the UNICEF/UNDP/World Bank/WHO Special
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